Ortho Biotech & Development, a unit of Cougar Biotechnology, Inc. has unblinded their Phase 3 study of abiraterone acetate plus prednisone. In the trial the abiraterone was used for the treatment of men with metastatic advanced prostate cancer has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel. [...]
At the ASCO Annual meeting in Orlando Florida, Cougar Biotechnology, Inc. announced perliminary results from their ongoing Phase II clinical trials of their much discussed investigational drug abiraterone acetate (CB7630). The company released some preliminary encouraging data in three separate poster presentations. First, I want to tell you what abiraterone acetate is. In scientific jargon [...]
There is some good news on the horizon, or at least we are setting up for the possibility of some future good news. Coming off of the recent news about the very successful phase II trial of CB7630 (abiraterone acetate), Cougar Biotechnology, Inc. has reached agreement with the FDA under a special protocol assessment (SPA) [...]
An announcement from Market Watch claims that Cougar Biotechnology has come to an agreement with the US Food & Drug Administration (FDA) to conduct an additional Phase III trial of abiraterone acetate in prostate cancer. The currently ongoing and much in demand Phase III trial of abiraterone acetate was designed for prostate cancer survivors who [...]
Today, Cougar Biotechnology, Inc. (NASDAQ:CGRB) unveiled the results from its ongoing Phase II clinical trial drug CB7630 (abiraterone acetate). The data was presented at the Prostate Cancer Foundation Scientific Retreat in Lake Tahoe, Nevada. The clinical trial, which is centered at the M.D. Anderson Cancer Center in Texas and was designed to look at the [...]
Posted on the Prostate Problems Mailing list about two months ago was a notice from Dr. Richard Lam about a clinical trial in which his office, Prostate Oncology Specialists, will participate. What I found particularly interesting in this trial is that it was evaluating a potential new drug, abiraterone acetate, which could be used after [...]
A recent announcement about the once daily oral drug abiraterone acetate (CB7630) indicated that some of the current trial results demonstrate some efficacy in men with hormone refractory prostate cancer. The positive results appeared at two different stages of the standard treatment process. Positive results were demonstrated both before and after the administration of chemotherapy. [...]
